Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
A trial to evaluate the tolerability and efficacy of SHR-A1921 in combination with adbelizumab and SHR-8068 with or without carboplatin in patients with advanced non-small cell lung cancer
Advanced Non-small Cell Lung Cancer
DRUG: SHR-A1921；Adebrelimab；SHR-8068；carboplatin
DLT, 21 days after the first dose|ORR based on RECIST v1.1 assessment., All enrolled subjects were evaluated every 6 or 9 weeks starting with the first dose, up to 2 years
Adverse event, All informed subjects signed informed consent from the beginning to the end of the safety follow-up period， up to 2 years|DCR based on RECIST v1.1 assessment, All enrolled subjects were evaluated every 6 or 9 weeks starting with the first dose, up to 2 years
A trial to evaluate the tolerability and efficacy of SHR-A1921 in combination with adbelizumab and SHR-8068 with or without carboplatin in patients with advanced non-small cell lung cancer